Advertisement

Zusammenfassung

Nach intravenöser Infusion von 1 mg/Std. erreicht die Nimodipinkonzentration ein mittleres Gleichgewicht von 11,9 μg/l nach 12–18 Std. (Rämsch et al. 1985a, b). Nach einmaliger oraler Applikation von 60 mg Nimodipin als Lösung wurde eine maximale Plasmakonzentration von 117 μg/l erreicht (Rämsch et al. 1985a, b). Dieselbe Dosis, als Kapsel verabreicht, ergab niedrigere Werte (62 μg/l). Nimodipin wird bei oraler Gabe als Lösung oder Kapsel sehr rasch resorbiert, wobei die maximale Plasmakonzentration innerhalb von 30–60 min erreicht wird. Bei einer Dosierung von 3 × 40 mg/Tag fand sich am 7. Behandlungstag eine mittlere maximal Plasma-Konzentration von 46 μg/l. Dabei variierten die individuellen Werte zwischen 17–80 μg/1 (Kirch et al. 1984). Es bestehen beträchtliche interindividuelle Absorptions- und Plasmakonzentrationsunterschiede, die jedoch nicht auf die unterschiedlichen Zubereitungsformen zurückzuführen sind (Gengo et al. 1987).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Auer LM, Mokry M (1986) Effect of topical nimodipine versus its ethanol-containing vehicle on cat pial arteries. Stroke 17: 225–228PubMedCrossRefGoogle Scholar
  2. Auer LM, Oberbauer RW, Schalk HV (1983) Human pial vascular reactions to intravenous Nimodipine-infusion during EC-IC bypass surgery. Stroke 14: 210–213PubMedCrossRefGoogle Scholar
  3. Auer LM, Suzuki A, Yasui N, Ito Z (1984) Intraoperative topical nimodipine after aneurysm clipping. Neurochirurgia (Stuttg) 27: 36–38Google Scholar
  4. Ban TA, Morey L, Aguglia E, Azzarelli O, Balsano F, Marigliano V, Caglieris N, Sterlicchio M, Capurso A, Tomasi NA et al. (1990) Nimodipine in the treatment of old age dementias. Prog Neuropsychopharmacol Biol Psychiatry 14: 525–551PubMedCrossRefGoogle Scholar
  5. Barnett GH, Bose B, Little JR, Jones SC, Friel HT (1986) Effects of nimodipine on acute focal cerebral ischemia. Stroke 17: 884–890PubMedCrossRefGoogle Scholar
  6. Bianchi AP, Viglianesi MS (1985) Hemorrheological effects of dihydropyridine calcium entry blockers. Naunyn Schmiedebergs Arch Pharmacol (Abstract no 154) 330: 87Google Scholar
  7. Bielenberg GW, Beck T, Sauer D, Burniol M, Krieglstein J (1987) Effects of cerebroprotective agents on cerebral blood flow and on postischemic energy metabolism in the rat brain. J Cereb Blood Flow Metab 7: 480–488PubMedCrossRefGoogle Scholar
  8. Disterhoft JF, Moyer JR, Thompson LT (1993) The calcium rationale in Alzheimer disease. Raven Press, New YorkGoogle Scholar
  9. Dorn M (1985) Effect of nimodipine on the wellbeing, symptoms and efficacy of ambulatory patients with cerebrovascular disorders. In: Betz E, Deck K, Hoffmeister F (eds) Nimodipine. Pharmacological and clinical properties. Proceedings of the First International Symposium, Munich, Feb 1984. Schattauer, Stuttgart New York, pp 295–304Google Scholar
  10. Fischhof PK (1993) Divergent neuroprotective effects of nimodipine in PDD and MID provide indirect evidence of disturbances in Ca2+ homeostasis in dementia. Meth Find Exp Clin Pharmacol 15: 549–555Google Scholar
  11. Fischhof PK, Bernhaut A, Friedmann A (1993) Senile dementia and calcium channel blockers: a review. Drugs of today 29: 57–95Google Scholar
  12. Fischhof PK, Rüther E, Wagner G, Litschauer G (1990) Therapieergebnisse mit Nimodipin bei primär degenerativer Demenz und Multiinfarktdemenz. Z Geriatrie 3: 320–327Google Scholar
  13. Fleckenstein-Grün G, Frey M, Makita Y, Byon YK (1985) New pharmacological aspects of various dihydropyridine calcium antagonists with regard to smooth muscle relaxation. In: Lichtlen PR (ed) Recent aspects in calcium antagonism. Schattauer, Stuttgart New York, pp 29–46Google Scholar
  14. Gaab MR, Haubitz I, Brawanski A, Korn A, Czech T (1985) Acute effects of nimodipine on the cerebral blood flow and intracranial pressure. Neurochirurgia (Stuttg) 28 [Suppl 1]: 93–99Google Scholar
  15. Gelmers HJ (1982) Effect of nimodipine (Bay e 9736) on postischaemic cerebrovascular reactivity, as revealed by measuring regional cerebral blood flow (rCBF). Acta Neurochir (Wien) 63: 283–290CrossRefGoogle Scholar
  16. Gengo FM, Fagan SC, Krol G, Bernhard H (1987) Nimodipine disposition and haemodynamic effects in patients with cirrhosis and agematched controls. Br J Clin Pharmacol 23: 47–53PubMedCrossRefGoogle Scholar
  17. Gioia AE, White RP, Bakhtian B, Robertson JT (1985) Evaluation of the efficacy of intrathecal nimodipine in canine models of chronic cerebral vasospasm. J Neurosurg 62: 721–728PubMedCrossRefGoogle Scholar
  18. Grobe Einsler R (1993) Clinical aspects of nimodipine. Clin Neuropharmacol 16 [Suppl 1]: 39–45CrossRefGoogle Scholar
  19. Harper AM, Craigen L, Kazda S (1981) Effect of the calcium antagonist, nimodipine, on cerebral blood flow and metabolism in the primate. J Cereb Blood Flow Metab 1: 349–356PubMedCrossRefGoogle Scholar
  20. Haws CW, Gourleyj K, Heistad DD (1983) Effects of nimodipine on cerebral blood flow. J Pharmacol Exp Ther 225: 24–28PubMedGoogle Scholar
  21. Held K, Boehme K, Rode PC (1985) Efficacy and tolerability of nimodipine in patients with old age cerebrovascular dysfunction. In: Betz E, Deck K, Hoffmeister F (eds) Nimodipine: pharmacological and clinical properties. Proceedings, 1st International Symposium, Munich, Feb 1984. Schattauer, Stuttgart New York, pp 289–292Google Scholar
  22. Herrschaft H (1992) Nimodipin. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka, Bd 5. Springer, Wien New York, S 261–289Google Scholar
  23. Hoffmeister F, Benz U, Heise A, Krause HP, Neuser V (1982) Behavioral effects of nimodipine in animals. Arzneimittelforschung 32: 347–360PubMedGoogle Scholar
  24. Kanda K, Flaim SF (1986) Effects of nimodipine on cerebral blood flow in conscious rat. J Pharmacol Exp Ther 236: 41–47PubMedGoogle Scholar
  25. Kanowski S, Fischhof P, Hirsemenzel R, Röhmel J, Kern U (1988) Wirksamkeitsnachweis von Antidementiva am Beispiel von Nimodipin-Ein Beitrag zur Entwicklung geeigneter klinischer Prüfmodelle. Z Gerontopsychol Psychiatr 1: 35–44Google Scholar
  26. Kapoula O, Lehrl S, Fischer B, Burkhard G, Schuback G (1990) Nimodipin bei Hirnleistungsstörungen im Alter — eine placebokontrollierte Doppelblindstudie in ärztlichen Praxen. Geriatrie und Rehabilitation 3: 135–146Google Scholar
  27. Kazda S, Hoffmeister F, Garthoff B, Towart R (1979) Prevention of the postischaemic impaired reperfusion of the brain by nimodipine (Bay e 9736). Acta Neurol Scand 60 [Suppl 72]: 302–303Google Scholar
  28. Kiesewetter H, Jung F, Radtke H, Roggenkamp G, Schneider R (1985) Investigation of the rheological effectiveness of nimodipine in comparison to other established rheologica with an in vitro stress model with calcium. In: Betz E (ed) Nimodipine. Pharmacological and clinical properties. Schattauer, Stuttgart New York, pp 127–135Google Scholar
  29. Kirch W, Rämsch KD, Duhrsen U, Ohnhaus EE (1984) Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Int J Clin Pharmacol Res 4: 381–384PubMedGoogle Scholar
  30. Krieglstein J (1990) Hirnleistungsstörungen — Pharmakologie und Ansätze für die Therapie. Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  31. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE (1992) beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12: 376–389PubMedGoogle Scholar
  32. Menazzi D, Montenegro R, Castro JM (1985) Nimodipine in the treatment of chronic cerebrovascular insufficiency. In: Betz E, Deck K, Hoffmeister F (eds) Nimodipine. Pharmacological and clinical properties. Proceedings, 1st International Symposium, Munich, Feb 1984. Schattauer, Stuttgart New York, pp 333–344Google Scholar
  33. Michenfelder JD, Milde JH (1987) Nimodipine does not affect cerebral lactate levels following complete ischemia in dogs. J Cereb Blood Flow Metab 7: 619–624PubMedCrossRefGoogle Scholar
  34. Mikus P, Aufdembrinke B (1985) Nimodipine, a centrally active calcium antagonist. Results of a clinico-psychometric study. In: Betz E, Deck K, Hoffmeister F (eds) Nimodipine. Pharmacological and clinical properties. Proceedings, 1st International Symposium, Munich, Feb 1984. Schattauer, Stuttgart New York, pp 329–331Google Scholar
  35. Mohamed AA, Gotoh O, Graham DI, Osborne KA, Mcculloch J, Mendelow AD, Teasdale GM, Harper AM (1985) Effect of pretreatment with the calcium antagonist nimodipine on local cerebral blood flow and histopathology after middle cerebral artery occlusion. Ann Neurol 18: 705–711PubMedCrossRefGoogle Scholar
  36. Morich FJ, Bieber F, Lewis JM, Kaiser L, Cutler NR, Escobar JI, Willmer J, Petersen RC, Reisberg B and the North American Nimodipine Study Group (1996) Nimodipin in the treatment of probable Alzheimer’s disease — results of two multicentre trials. Clin Drug Invest 11:185–195CrossRefGoogle Scholar
  37. Morocutti C, Mattioli GL, Pierelli F, Prezessere G, Stefano E, Peppe A, Rizzo PA (1985) Effects of nimodipine on cefazolin induced epilepsy in rabbits. J Neurol [Suppl]: 274Google Scholar
  38. Mück W, Ahr G, Kuhlmann J (1995) Nimodipine. Potential for drug-drug interactions in the elderly. Drugs Aging 6: 229–242PubMedCrossRefGoogle Scholar
  39. Nosko M, Weir B, Krueger C, Cook D, Norris S, Overton T, Boisvert D (1985) Nimodipine and chronic vasospasm in monkeys, part 1. Clinical and radiological findings. Neurosurgery 16: 129–136PubMedCrossRefGoogle Scholar
  40. Parnetti L, Senin U, Carosi M, Baasch H (1993) Mental deterioration in old age: results of two multicenter, clinical trials with nimodipine. The Nimodipine Study Group. Clin Ther 15: 394–406PubMedGoogle Scholar
  41. Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, Humphrey PR, Lang DA, Nelson R, Richards P et al. (1989) Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 298: 636–642PubMedCrossRefGoogle Scholar
  42. Rämsch KD, Ahr G, Tettenborn D, Auer LM (1985a) Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. Neurochirurgia 28: 74–78PubMedGoogle Scholar
  43. Rämsch KD, Graefe KH, Sommer J (1985b) Pharmacokinetics and metabolism of nimodipine. In: Betz E, Deck K, Hoffmeister F (eds) Nimodipine: pharmacological and clinical properties. Schattauer, Stuttgart New York, pp 147–161Google Scholar
  44. Schmage N, Dycka J (1991) Auswertung von verschiedenen psychometrischen Verfahren aus klinischen Studien mit Nimodipin. In: Möller HJ (Hrsg) Hirnleistungsstörungen im Alter. Springer, Berlin Heidelberg New York Tokyo, S 97–104CrossRefGoogle Scholar
  45. Schmunk GA, Lefer AM (1982) Anti-aggregatory actions of calcium channel blockers in cat platelets. Res Commun Chem Pathol Pharmacol 35: 179–187PubMedGoogle Scholar
  46. Schuurmann T, Traber J (1989a) Old rats as an animal model for senile dementia: behavioural effects of nimodipine. In: Bergener M, Reisberg B (eds) Diagnosis and treatment of senile dementia. Springer, Berlin Heidelberg New York Tokyo, pp 295–307CrossRefGoogle Scholar
  47. Schuurmann T, Traber J (1989b) Effects of nimodipine on behaviour of old rats. In: Traber J, Gispen WH (eds) Nimodipine and central nervous system function: new vistas. Schattauer, Stuttgart New York, pp 195–208Google Scholar
  48. Scriabine A, Teasdale CM, Tettenborn D, Young W (1991) Nimodipine — Pharmacological and clinical results in cerebral ischemia. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  49. Smith JJ, Kagström E, Rosen I, Siesjö BK (1983) Effect of the calcium antagonist nimodipine on the delayed hypoperfusion following incomplete ischaemia in the rat. J Cereb Blood Flow Metab 3: 543–546PubMedCrossRefGoogle Scholar
  50. Steen PA, Newberg LA, Milde JH, Michenfelder JD (1983) Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischemia in the dog. J Cereb Blood Flow Metab 3: 38–43PubMedCrossRefGoogle Scholar
  51. Tobares N, Pedromingo A, Bigorra J (1989) Nimodipine treatment improves cognitive functions in vascular dementia. In: Bergener M, Reisberg B (eds) Diagnosis in the treatment of senile dementia. Springer, Berlin Heidelberg New York Tokyo, pp 360–365CrossRefGoogle Scholar
  52. Towart R, Kazda S (1985) Effects of calcium antagonist nimodipine on isolated cerebral vessels. In: Betz E, Deck K, Hoffmeister F (eds) Nimodipine: pharmacological and clinical properties. Schattauer, Stuttgart New York, pp 147–161Google Scholar
  53. Ulrich G (1987) Zur Wirkung von Nimodipin auf die topische Verteilung der absoluten Alphaleistung im EEG sowie die aktuelle Befindlichkeit gesunder Probanden. Arzneimittelfor-schung/Drug Res 37: 541–545Google Scholar
  54. Ulrich G, Stieglitz RD (1988) Effect of nimodipine upon electroencephalographic vigilance in elderly persons with minor impairment of brain functions. Arzneimittelfor-schung/Drug Res 38: 392–396Google Scholar
  55. Wascher E, Verleger R, Kömpf D (1994) Die Messung von Therapieeffekten bei dementen Patienten mittels kognitiver Komponenten der evozierten Potentiale. Focus MUL 11: 36–41Google Scholar
  56. Young WL, Josovitz K, Morales O, Chien S (1987) The effect of nimodipine on post-ischemic cerebral glucose utilization and blood flow in the rat. Anesthesiology 67: 54–59PubMedCrossRefGoogle Scholar
  57. Zhang J, Cheng X (1986) Effects of three cerebral vasodilators — nimodipine, nifedipine and vincamine on chemical-induced amnesia in rodents. Acta Pharm Sin 21: 731–735Google Scholar
  58. Zirm B, Steinwachs KC, Pracher G, Zirm A, Zimmermann-Meinzinger S (1994) Effekte von Nimodipin und Piracetam auf das kognitive Leistungstempo und die klinische Symptomatik bei Patienten mit vaskulärer und degenerativer Demenz — Ergebnisse einer randomisierten klinischen Vergleichsstudie. Z Geronto-psychol Psychiatr 157–168Google Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • H.-J. Möller

There are no affiliations available

Personalised recommendations